NCT06231381View on ClinicalTrials.gov

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

February 13, 2025

Study Completion Date

November 30, 2025

Conditions
Generalized Pustular Psoriasis (GPP)
Interventions
DRUG

HB0034

Anti-IL-36R antibody

OTHER

Placebo

non-biologically active drug

Trial Locations (2)

Unknown

RECRUITING

Peking University People's Hospital (PKUPH), Beijing

RECRUITING

Shanghai Huaota Biopharmaceutical Co., Ltd, Shanghai

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY